Operationalizing NGS Across Biologics Development: An AI-Enabling Digital Infrastructure from Discovery to Manufacturing

September 24, 2026

Next-generation sequencing (NGS) is rapidly becoming a critical analytical technology across the biologics lifecycle, enabling applications ranging from e.g., antibody discovery and cell line development (CLD) to process characterization, biosafety testing, quality control, and manufacturing release. While the scientific value of NGS is well established, many organizations continue to face significant challenges operationalizing NGS at enterprise scale. Fragmented workflows, disconnected data environments, the need to make advanced bioinformatics workflows accessible and reproducible across functions, and growing regulatory expectations often prevent the full realization of NGS-driven insights.

Genedata Selector^® addresses these challenges by unifying traditionally siloed NGS applications within a single enterprise platform. Rather than relying on separate solutions for discovery, development, quality control (QC), and manufacturing, organizations can establish a common digital foundation that enables standardized analytics, ensures data integrity, and supports regulatory readiness across the entire biologics lifecycle. By transforming diverse datasets into FAIR, structured, and AI/ML-ready assets, the platform accelerates development timelines, improves operational efficiency, and fosters cross-functional collaboration, enabling data-driven decision-making across the biologics development. In doing so, it provides the digital foundation for AI-enabling, predictive biologics development and manufacturing.